Logo image of SCYX

SCYNEXIS INC (SCYX) Stock Fundamental Analysis

NASDAQ:SCYX - Nasdaq - US8112922005 - Common Stock - Currency: USD

0.7699  0 (-0.12%)

After market: 0.76 -0.01 (-1.29%)

Fundamental Rating

3

SCYX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of SCYX have multiple concerns. SCYX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

SCYX had negative earnings in the past year.
In the past year SCYX has reported a negative cash flow from operations.
SCYX had negative earnings in 4 of the past 5 years.
In the past 5 years SCYX reported 4 times negative operating cash flow.
SCYX Yearly Net Income VS EBIT VS OCF VS FCFSCYX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

1.2 Ratios

SCYX has a Return On Assets (-23.49%) which is in line with its industry peers.
Looking at the Return On Equity, with a value of -38.65%, SCYX is in line with its industry, outperforming 56.57% of the companies in the same industry.
Industry RankSector Rank
ROA -23.49%
ROE -38.65%
ROIC N/A
ROA(3y)-14.27%
ROA(5y)-24.82%
ROE(3y)-636.53%
ROE(5y)-446.25%
ROIC(3y)N/A
ROIC(5y)N/A
SCYX Yearly ROA, ROE, ROICSCYX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

1.3 Margins

SCYX has a Gross Margin of 100.00%. This is amongst the best in the industry. SCYX outperforms 99.49% of its industry peers.
SCYX's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for SCYX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 100%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.8%
GM growth 5YN/A
SCYX Yearly Profit, Operating, Gross MarginsSCYX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K

More info and screens

3

2. Health

2.1 Basic Checks

SCYX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SCYX has more shares outstanding
SCYX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for SCYX is higher compared to a year ago.
SCYX Yearly Shares OutstandingSCYX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
SCYX Yearly Total Debt VS Total AssetsSCYX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -5.98, we must say that SCYX is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of SCYX (-5.98) is worse than 64.14% of its industry peers.
SCYX has a Debt/Equity ratio of 0.25. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.25, SCYX is in line with its industry, outperforming 44.95% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF N/A
Altman-Z -5.98
ROIC/WACCN/A
WACC9.79%
SCYX Yearly LT Debt VS Equity VS FCFSCYX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

A Current Ratio of 3.00 indicates that SCYX has no problem at all paying its short term obligations.
SCYX has a Current ratio of 3.00. This is comparable to the rest of the industry: SCYX outperforms 53.54% of its industry peers.
A Quick Ratio of 3.00 indicates that SCYX has no problem at all paying its short term obligations.
SCYX has a Quick ratio (3.00) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3
Quick Ratio 3
SCYX Yearly Current Assets VS Current LiabilitesSCYX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for SCYX have decreased strongly by -133.33% in the last year.
SCYX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -97.33%.
SCYX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 99.01% yearly.
EPS 1Y (TTM)-133.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.92%
Revenue 1Y (TTM)-97.33%
Revenue growth 3Y-34.22%
Revenue growth 5Y99.01%
Sales Q2Q%-83.15%

3.2 Future

SCYX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.57% yearly.
SCYX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 37.02% yearly.
EPS Next Y26.98%
EPS Next 2Y89.42%
EPS Next 3Y83.78%
EPS Next 5Y23.57%
Revenue Next Year58.74%
Revenue Next 2Y137.01%
Revenue Next 3Y132.51%
Revenue Next 5Y37.02%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
SCYX Yearly Revenue VS EstimatesSCYX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M
SCYX Yearly EPS VS EstimatesSCYX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -10 -20 -30 -40 -50

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

SCYX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SCYX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SCYX Price Earnings VS Forward Price EarningsSCYX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SCYX Per share dataSCYX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

SCYX's earnings are expected to grow with 83.78% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y89.42%
EPS Next 3Y83.78%

More info and screens

0

5. Dividend

5.1 Amount

SCYX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SCYNEXIS INC

NASDAQ:SCYX (5/22/2025, 8:00:02 PM)

After market: 0.76 -0.01 (-1.29%)

0.7699

0 (-0.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-06 2025-08-06/amc
Inst Owners32.1%
Inst Owner Change-2.12%
Ins Owners2.4%
Ins Owner Change11.04%
Market Cap30.01M
Analysts84.44
Price Target5.1 (562.42%)
Short Float %1.69%
Short Ratio5.8
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)40.2%
Min EPS beat(2)20.51%
Max EPS beat(2)59.89%
EPS beat(4)3
Avg EPS beat(4)34.94%
Min EPS beat(4)-45.6%
Max EPS beat(4)104.96%
EPS beat(8)5
Avg EPS beat(8)3.39%
EPS beat(12)8
Avg EPS beat(12)12.39%
EPS beat(16)11
Avg EPS beat(16)24.78%
Revenue beat(2)0
Avg Revenue beat(2)-90.07%
Min Revenue beat(2)-90.6%
Max Revenue beat(2)-89.53%
Revenue beat(4)2
Avg Revenue beat(4)82.3%
Min Revenue beat(4)-90.6%
Max Revenue beat(4)344.25%
Revenue beat(8)5
Avg Revenue beat(8)78.47%
Revenue beat(12)6
Avg Revenue beat(12)45.74%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-75%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-96.77%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-65.87%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.01
P/FCF N/A
P/OCF N/A
P/B 0.54
P/tB 0.54
EV/EBITDA N/A
EPS(TTM)-0.44
EYN/A
EPS(NY)-0.32
Fwd EYN/A
FCF(TTM)-0.62
FCFYN/A
OCF(TTM)-0.62
OCFYN/A
SpS0.1
BVpS1.41
TBVpS1.41
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -23.49%
ROE -38.65%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 100%
FCFM N/A
ROA(3y)-14.27%
ROA(5y)-24.82%
ROE(3y)-636.53%
ROE(5y)-446.25%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.8%
GM growth 5YN/A
F-Score2
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3
Quick Ratio 3
Altman-Z -5.98
F-Score2
WACC9.79%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-133.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.92%
EPS Next Y26.98%
EPS Next 2Y89.42%
EPS Next 3Y83.78%
EPS Next 5Y23.57%
Revenue 1Y (TTM)-97.33%
Revenue growth 3Y-34.22%
Revenue growth 5Y99.01%
Sales Q2Q%-83.15%
Revenue Next Year58.74%
Revenue Next 2Y137.01%
Revenue Next 3Y132.51%
Revenue Next 5Y37.02%
EBIT growth 1Y-151.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-139.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-139.91%
OCF growth 3YN/A
OCF growth 5YN/A